Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent KATP Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome
Cells · 2023
DOI: 10.3390/cells12060928 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Rosa Scala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy. Hauptthemen laut MEDLINE: Zoledronic Acid, Muscle, Skeletal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Società Italiana di Farmacologia (SIF), “Erasmus + for Traineeship” fellowship.
Abstract (Originalsprache)
Cantú syndrome (CS) is caused by the gain of function mutations in the ABCC9 and KCNJ8 genes encoding, respectively, for the sulfonylureas receptor type 2 (SUR2) and the inwardly rectifier potassium channel 6.1 (Kir6.1) of the ATP-sensitive potassium (KATP) channels. CS is a multi-organ condition with a cardiovascular phenotype, neuromuscular symptoms, and skeletal malformations. Glibenclamide has been proposed for use in CS, but even in animals, the drug is incompletely effective against severe mutations, including the Kir6.1wt/V65M. Patch-clamp experiments showed that zoledronic acid (ZOL) fully reduced the whole-cell KATP currents in bone calvaria cells from wild type (WT/WT) and heterozygous Kir6.1wt/V65MCS mice, with IC50 for ZOL block < 1 nM in each case. ZOL fully reduced KATP current in excised patches in skeletal muscle fibers in WT/WT and CS mice, with IC50 of 100 nM in each case. Interestingly, KATP currents in the bone of heterozygous SUR2wt/A478V mice were less sensitive to ZOL inhibition, showing an IC50 of ~500 nM and a slope of ~0.3. In homozygous SUR2A478V/A478V cells, ZOL failed to fully inhibit the KATP currents, causing only ~35% inhibition at 100 μM, but was responsive to glibenclamide. ZOL reduced the KATP currents in Kir6.1wt/VMCS mice in both skeletal muscle and bone cells but was not effective in the SUR2[A478V] mice fibers. These data indicate a subunit specificity of ZOL action that is important for appropriate CS therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
- Center for the Investigation of Membrane Excitability Diseases, Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
ORCID-Profile: Maria Grazia Perrone, Antonio Scilimati
Förderung
- NHLBI NIH HHS
- Società Italiana di Farmacologia (SIF)
- “Erasmus + for Traineeship” fellowship
Zitieren
APA
Scala, R., Maqoud, F., McClenaghan, C., Harter, T. M., Perrone, M. G., Scilimati, A., Nichols, C. G., & Tricarico, D. (2023). Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent KATP Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome. Cells. https://doi.org/10.3390/cells12060928
Vancouver
Scala R, Maqoud F, McClenaghan C, Harter TM, Perrone MG, Scilimati A, et al. Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent KATP Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome. Cells. 2023. doi:10.3390/cells12060928
BibTeX
@article{Scala2023,
author = {Scala, Rosa and Maqoud, Fatima and McClenaghan, Conor and Harter, Theresa M and Perrone, Maria Grazia and Scilimati, Antonio and Nichols, Colin G and Tricarico, Domenico},
title = {Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent KATP Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12060928}
}
EUVIMED